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Type 2 diabetes mellitusBackground: GlycA is a recently developed glycoprotein biomarker of systemic inﬂammation that may be
predictive of incident type 2 diabetes mellitus (T2DM).
Methods: Analytical performance of the GlycA test, measured on the Vantera® Clinical Analyzer, was evaluated.
To test its prospective associationwith T2DM, GlycAwasmeasured in 4524 individuals from the PREVEND study
and a survival analysis was performed with a mean follow-up period of 7.3 y.
Results: Imprecision for the GlycA test ranged from 1.3–2.3% and linearity was established between 150 and
1588 μmol/l. During the follow-up period, 220 new T2DM cases were ascertained. In analyses adjusted for
relevant covariates, GlycAwas associatedwith incident T2DM; hazard ratio (HR) for the highest vs. lowest quar-
tile 1.77 [95% Conﬁdence Interval (CI): 1.10–2.86, P = 0.01], whereas the association of high sensitivity
C-reactive protein (hsCRP) with T2DM was not signiﬁcant. GlycA remained associated with incident T2DM
after additional adjustment for hsCRP; HR 1.71 [1.00–2.92, P = 0.04]. A multivariable adjusted analysis of
dichotomized subgroups showed that the hazard for incident T2DM was highest in the subgroup with high
GlycA and low hsCRP (P = 0.03).
Conclusions: The performance characteristics of the GlycA test reveal that it is suitable for clinical applications,
including assessment of the risk of future T2DM.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
GlycA is a recently developed nuclear magnetic resonance (NMR)
spectroscopy-measured biomarker of systemic inﬂammation [1–7].
The GlycA NMR signal arises from the N-acetyl glucosamine (GlcNAc)
residues on the carbohydrate side-chains of acute phase proteins,
mainly α1-acid glycoprotein (orosomucoid), α1-antitrypsin, α1-
antichymotrypsin, haptoglobin and transferrin [1,6]. Hence, GlycA is a
composite biomarker that integrates both the protein levels and glyco-
sylation states of themost abundant acute phase proteins present in the
circulation [1]. GlycA has been demonstrated to be associated with
common markers of inﬂammation such as high sensitivity C-reactive
protein (hsCRP), ﬁbrinogen, interleukin-6 and serum amyloid A [1–7].
Recently it was reported that GlycA is related to the leptin/adiponectinER, Justiﬁcation for the Use of
uating Rosuvastatin; PREVEND,
udy; RA, rheumatoid arthritis;
of America® Holdings, United
y).
. This is an open access article underratio, suggesting that adipose tissue-associated low-grade inﬂammation
could be involved in the regulation of acute phase proteins [5]. Similar
to hsCRP, GlycA was found to be higher in subjects with metabolic
syndrome and was positively correlated with body mass index (BMI)
and insulin resistance as assessed by homeostasis model assessment
(HOMA-IR) [4,5,7].
GlycA is elevated in several chronic inﬂammatory diseases and asso-
ciated with disease incidence [8–11]. GlycA was elevated in patients
with various autoimmune diseases and was associated with disease
activity and coronary atherosclerosis in rheumatoid arthritis patients
[3,6,12,13]. In the Women's Health Study (WHS) [8], the Prevention of
Renal and Vascular End-stage Disease (PREVEND) study [9] and the
JUPITER trial [10], GlycA was associated with incident cardiovascular
disease (CVD) events, independent of traditional risk factors. GlycA
was also found to predict incident type 2 diabetes mellitus (T2DM)
in a large population of healthy women [11]. These data raise the possi-
bility that GlycA provides added value for the evaluation of CVD and
diabetes risk.
Recently a clinical NMR instrument, the Vantera® Clinical Analyzer,
has been developed that addresses the limiting factors of research
instruments and allows lipoprotein measurements to be performed inthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Drug Administration (FDA)-cleared in vitro diagnostic device, is able
to quantify additional analytes from the NMR LipoProﬁle® test spectra,
including GlycA and metabolites such as branched chain amino acids
[14,15]. Although the GlycA assay has been previously described [1],
the analytical performance of the GlycA assay on the Vantera Clinical
Analyzer, the instrument thatwill be reportingGlycA results as a clinical
diagnostic test, has not been reported to date.
2. Materials and methods
2.1. Study design
The PREVEND study was approved by the local medical ethics
committee, University Medical Center Groningen, The Netherlands;
each participant provided written informed consent. Details of the
study design and recruitment have been described elsewhere [www.
PREVEND.org] [16].
2.1.1. Study participants
Brieﬂy, the PREVEND study is a Dutch cohort drawn from the general
population of the city of Groningen. After exclusion of subjects with
insulin-treated diabetes and pregnant women, all subjects with a uri-
nary albumin concentration ≥ 10 mg/l were invited to participate
(n = 7768), of whom 6000 accepted. In addition, a random sample of
2592 individuals with a urinary albumin concentration b 10 mg/l wasFig. 1. Flowchart depicting PREVEND participants incincluded. These 8592 subjects (aged 28–75 years) completed the base-
line survey (1997–1998). The second screening, which was the starting
point of the current study, took place between 2001 and 2003 (n =
6894). GlycA and hsCRP were measured in 5526 subjects from the
second screening in whom samples of sufﬁcient quality and quantity
were available. For the current study subjects with missing data on
diabetes at baseline (n= 40), subjects with prevalent T2DM at baseline
(n = 358) and those with missing data on follow-up (n = 604) were
excluded, leaving 4524 subjects for the present analysis (Fig. 1).
2.1.2. Follow-up and outcome
Follow-up time was deﬁned as the period between the second
screening round (baseline) and the date of ascertainment of T2DM.
Follow-up time was censored at 8.5 years. In case a person moved
to an unknown destination, census date was date of removal from
the municipal registry. Incident cases of diabetes was ascertained if
one or more of the following criteria were met: 1) fasting plasma
glucose ≥7.0 mmol/l (126 mg/dL); 2) random sample plasma glucose
≥11.1 mmol/l (200 mg/dL); 3) self-report of a physician diagnosis of
T2DM and 4) initiation of glucose-lowering medication use, retrieved
from a central pharmacy registry [17,18].
2.1.3. Laboratory analysis in PREVEND
Venous blood was obtained at each screening round after
an overnight fast. Plasma samples were prepared by centrifugation at
4 °C. EDTA plasma samples were stored at −80 °C until thawed forluded or excluded for the purposes of this study.
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LipoScience, Laboratory Corporation of America Holdings for testing on
the Vantera Clinical Analyzer. NMR spectra were collected and GlycA
values were quantiﬁed as described above [1]. Total cholesterol (TC),
high density lipoprotein cholesterol (HDL-C) and triglycerides (TG)
were measured on a Beckman Coulter® AU680 Analyzer. hsCRP and
glucose were determined using standard laboratory protocols [19].
2.1.4. Statistical analyses for the PREVEND study
All statistical analyses were carried out using SPSS ver 22.0. Data are
presented as mean ± standard deviation (SD), median (interquartile
range) and percentages. For all analyses, 2-sided P b 0.05 was consid-
ered statistically signiﬁcant, except for interaction terms for which the
level of signiﬁcance was set at P b 0.10. Baseline characteristics were
calculated across sex-stratiﬁed quartiles of GlycA. P-values across
quartiles of GlycA were determined by linear regression for continuous
variables or chi-square test for categorical variables.
Cox proportional hazards regression analysis was performed to
examine the associations across quartiles calculated in the whole
study population of GlycA and hsCRP with the risk of developing
T2DM. In addition, hazards were calculated per 1 SD increment of
GlycA and hsCRP. Hazard ratios (HR) were expressed with 95% conﬁ-
dence intervals (CI). TG and hsCRP were log transformed when used
as a continuous variable in the analysis. In order to test if each of the bio-
markers in the highest range had a different association with incident
T2DM vs. both biomarkers or one of these biomarkers in the lowest
range the joint associations of GlycA and hsCRP with outcome were
evaluated by dichotomizing the distribution of GlycA and hsCRP accord-
ing to cut points at the highest quartile of GlycA (N384 μmol/l) and the
highest quartile of hsCRP (N2.83 mg/l).
Given the enrichment of subjects with microalbuminuria in the
PREVEND population, we also performed a secondary analysis in which
we accounted for the sampling design of the study, with respect to en-
richment of subjects with a urinary albumin concentration N 10 mg/l,
by specifying stratum-speciﬁc baseline hazard functions.
2.2. Analytical validation studies for the GlycA test
For the analytical validation studies, serum samples were collected
from healthy volunteers in the United States of America (USA). These
studies were cleared by an Institutional Review Board. For both the
analytical validation and PREVEND studies, all donors signed consent
forms and the studies were conducted in accordance with The Code of
Ethics of the World Medical Association (Declaration of Helsinki).
2.2.1. Specimen collection and preparation
Control serum pools and specimens were purchased and prepared
as previously described [14,15]. All studies were performed in NMR
LipoProﬁle® (LipoScience) serum separator tubes (#456,293/455,232;
Greiner Bio-One®), also known as LipoTubes® (LipoScience), unless
otherwise indicated.
2.2.2. Acquisition of NMR spectra and data processing
NMR spectra were acquired at the Clinical Laboratory Improvement
Amendments (CLIA) approved laboratory at Laboratory Corporation of
America® Holdings as previously described using the Vantera Clinical
Analyzer, a 400 MHz NMR spectrometer [14,15]. Typically, 2 levels of
serum controls were included at the beginning and end of each speci-
men run. Data acquisition on the Vantera was accomplished in a similar
fashion to the NMR Proﬁler platformwith the exception that water was
suppressed using the WET solvent suppression technique [14,20,21].
NMR spectral data were acquired as 3 blocks of 4 scans for a total acqui-
sition time of 48 s and a sweepwidth of 4496.4Hz and 9024 data points.
The signal peak appearing at 2.00 ppm, named GlycA, which lies
outside of the spectral region used to calculate the lipoprotein informa-
tion, was quantiﬁed as previously described in detail [1]. GlycA is not ahomogeneous signal from a single molecular species, but rather a com-
posite signal arising from the superposition of slightly offset N-acetyl
methyl group resonances from a subset of mobile GlcNAc residues on
the glycan branches of abundant glycoproteins [6]. It is only the GlcNAc
residues in β(1 → 2) or β(1 → 6) linkage with a preceding mannose
residue that give rise to N-acetyl methyl resonances at the 2.00 ±
0.01 ppm GlycA position [1]. The units for the GlycA signal represent
the number of GlcNAc residues in μmol/l. These particular residues can
be found on many glycosylated proteins however, the glycoproteins
that circulate at N10 μM and are highly glycosylated make the largest
contributions to the composite GlycA signal (e.g. α1-acid glycoprotein
(orosomucoid), α1-antitrypsin, α1-antichymotrypsin, haptoglobin
and transferrin) [1,6].
2.2.3. Assay performance testing
Sensitivity, imprecision and linearity were determined according to
Clinical and Laboratory Standards Institute (CLSI) guidelines as previ-
ously described [14,15,22–24]. For linearity testing, the high GlycA
serum pool was obtained by the addition of α1-acid glycoprotein, the
most abundant protein that contributes to the GlycA signal [1].
2.2.4. Method and tube comparisons
Method comparison studies consistent with CLSI guidelines were
performed to ensure that the performance of the GlycA test on the
Vantera Clinical Analyzer was similar to the GlycA test run on the
NMR Proﬁler [1]. Samples (n = 631) were tested in singlicate on the
reference (Proﬁler) and comparator (Vantera Clinical Analyzer) NMR
systems over a period of 5 days. The correlation between results gener-
ated on the two NMR platformswas evaluated using Deming regression
analysis. Blood from 46 donors was drawn into three different tubes:
LipoTube (serum), BD Vacutainer® serum tube (red top, no gel barrier)
and K2EDTA plasma tube. GlycA was measured for a total of 50 speci-
mens. Results for conventional serum and EDTA plasma tubes were
compared to results for the LipoTube by linear regression.
2.2.5. Reference interval and interfering substance studies
To determine the reference range for the GlycA assay, samples
from healthy adult men and non-pregnant women between the ages
of 18 and 84 (n = 450) were collected in BD Vacutainer serum tubes
(red top, no gel barrier). A description of this study population has
been reported [14]. The GlycA reference range was estimated using
non-parametric analyses with reference limits at the 2.5th and 97.5th
percentiles according to the nonparametric method described in CLSI
guidelines [25]. The reference intervals for men and women were com-
pared by assessing their median values by Mann–Whitney test. A total
of 7 endogenous and 23 exogenous substances were tested in vitro for
possible assay interference consistent with CLSI guidelines [26], as pre-
viously described [14,15].
2.2.6. Stability testing
2.2.6.1. Refrigerated stability. Serum samples obtained from 3 separate
studies of 10 donors each (n = 30) were used to assess stability of
GlycA. Samples were stored at 4 °C and aliquots were tested daily for
12 days. Daily mean results for all donors were evaluated with accept-
able differences falling within ±10% of the day 0 (draw day) mean.
2.2.6.2. Room temperature stability. Serum samples obtained from 12
donors were used to assess the stability of GlycA at room temperature
over time. Samples were allowed to sit at room temperature for 24 h.
Aliquots of the serum samples were tested at the following time points:
0, 1, 2, 4, 6, 8 and 24 h.
2.2.6.3. Freeze–thaw stability. A set of 3 pooled serum samples (low, mid
and high analyte concentrations) was used to assess the stability of
GlycA after 3 freeze–thaw cycles. One aliquot fromeachof the 3 samples
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−80 °C. After 24 h, all aliquotswere thawedunassisted at room temper-
ature for 1 h. Once thawed, 1 aliquot from each of the 3 samples was
testedwhile the remaining sets of aliquots were returned to the freezer.
This process continued until data for 3 freeze–thaw cycles were
collected.
2.3. Statistical analysis
Analytical validation data was calculated using either Excel Analyse-
it® or GraphPad Prism ver 6.0 software.
3. Results
3.1. Analytical performance of the GlycA assay
The analytical performance of the GlycA assay, as measured on the
Vantera Clinical Analyzer, was assessed for the ability to accurately
quantify the NMR signal at 2.00 ppm in spectra acquired from serum
samples. Because the GlycA signal arises from circulating glycosylated
proteins and it is not possible to remove all proteins from a serum spec-
imen, limits of blank (LOB) and detection (LOD) could not be deter-
mined by traditional means. However, testing of ﬁve serum pools,
with GlycA ranging from 57 to 166 μmol/l, gave CVs b7.6% and a func-
tional sensitivity or limit of quantitation (LOQ) of 18 μmol/l. Because
the calculated LOQ was lower than the lowest concentration measured,
57 μmol/l should be considered the LOQ for GlycA. Serum pool samples
with three varying concentrations of GlycA (low, intermediate and
high) were tested for intra-assay (within-run) and inter-assay (with-
in-lab) precision. The CV for the GlycA assay ranged from 1.3–1.8%
for within-run and 1.9–2.3% for within-lab imprecision (Table 1). In
order to test the ability of the assay to measure the GlycA NMR signal,
the measured values (n = 10 serum pools) were plotted against the
actual or expected concentrations. Linearity of GlycAwas demonstrated
throughout the reportable range of 150 to 1588 μmol/l with a correla-
tion coefﬁcient (R2) of 0.998 (Fig. 2A).
The linear regression for the GlycA data (n= 631), with the Proﬁler
results as the referencemethod, produced a slope (95% CI) of 1.00 (0.99
to 1.01), intercept of 4.60 (−1.15 to 10.35), and correlation coefﬁcient
(R2) of 0.983 (data not shown). Deming regression produced a slope
of 1.01 (1.00 to 1.02) and an intercept of 0.09 (−5.12 to 5.30)
(Fig. 2B). Differences between the GlycA values and the Deming regres-
sion line (residuals) were plotted against the estimated concentration
of GlycA. The points on the residuals plot were randomly dispersed
around the horizontal axis, suggesting that the results of the two assays
were linearly related with no signiﬁcant bias and no apparent outliers
(Fig. 2C).
Serum specimens from a population of healthy individuals (n =
450) were used to determine the reference interval for the GlycA test.Table 1
Within-run andwithin-laboratory imprecision for GlycAmeasured on the Vantera Clinical
Analyzer.
GlycA (μmol/l)
Low Intermediate High
Within-runa
Mean 344.1 460.9 649.9
SD 6.3 7.7 8.7
CV 1.8% 1.7% 1.3%
Within-laboratoryb
Mean 342.6 463.7 667.0
SD 7.9 10.3 12.5
CV 2.3% 2.2% 1.9%
a Based on 1 run of 20 tests.
b Based on CLSI guidelines tested using 3 serum pools, 2 runs per day in duplicate, for
20 days (total n = 80).Table 2 shows the distribution of GlycA values in this population. The
mean GlycA value was 386 ± 60 μmol/l, the median was 379 μmol/l
and the reference interval (2.5–97.5th percentile) was 288–518 μmol/l
(Table 2). In women, the mean GlycA value was 395 ± 60 μmol/l, the
median was 388 μmol/l, and the reference interval was 299–522 μmol/l.
In men, the mean GlycA value was 370 ± 57 μmol/l, the median was
366 μmol/l and the reference interval was 273–487 μmol/l. There was a
statistically signiﬁcant difference between the means and medians for
men and women (both P-values b0.0001).
Seven endogenous substances normally found circulating in blood
and 22 exogenous substances, previously used to test for interference
with quantiﬁcation of LDL-P [14] and HDL-P [15], were evaluated for
potential interference with the GlycA test. Only hemoglobin, at levels
which may occur in grossly hemolyzed specimens (≥20 mg/dL), re-
duced GlycA concentrations by approximately 20%.
Several types of specimen collection tubes were compared to
LipoTubes for their suitability in the GlycA assay. Linear regression
analyses were performed and the resulting lines had slopes of 0.94
(R2 = 0.99) for plain red-top serum tubes (no gel barrier) and 0.98
(R2= 0.98) for EDTA plasma tubes. Plain red-top serum showed no sig-
niﬁcant bias based on either 95% conﬁdence intervals around the corre-
lation slope and intercept or estimation of bias from Bland-Altman
residual plots. Measurements from EDTA plasma specimens, however,
were on average 3–5% lower than from serum specimens.
The stability of GlycA as measured on the Vantera Clinical Analyzer
was evaluated in 30 serum samples stored for up to 12 days at 4 °C.
Measurements were deemed acceptable if they were within 10% of
the day 0 mean GlycA. Results demonstrated GlycA was stable out to
day 12 at 4 °C with changes ≤3.7% and no trend toward higher or
lower values (data not shown). Additional stability studies revealed
that GlycA values were stable up to 24 h at room temperature, when
specimens were frozen up to 24 months and after being frozen and
thawed up to 3 times.When preparing serum specimens, centrifugation
could be delayed up to 24 h, when refrigerated after clotting, without
experiencing a signiﬁcant change in GlycA values.
3.2. Associations of GlycA with incident T2DM in PREVEND
Of the 6894 PREVEND participants that completed the second round
of screening, 4524 subjects were included in this study (Fig. 1). Subjects
were excluded if they were missing data for GlycA, hsCRP or informa-
tion regarding prevalent T2DM, at baseline or follow-up. Subjects
were also excluded if they had T2DM at baseline. After a median (inter-
quartile range [IQR]) follow-up period of 7.3 (5.9–7.6) y, 220 incident
cases of T2DMwere ascertained. Baseline clinical and laboratory charac-
teristics of the cohort are shown in Table 3. Participants with higher
levels of GlycAweremore likely to be older and tended to have a higher
BMI, blood pressure, glucose and hsCRP levels. They also had higher TC
and TG levels and lower HDL-C, andweremore likely to be on lipid low-
ering medications. Additionally, they were more likely to be current
smokers and less likely to consume alcohol.
Cox proportional hazards regression was used to evaluate the associ-
ation of GlycA and hsCRP with incident T2DM (Table 4). GlycA predicted
incident T2DM in models adjusted for age, sex, and additionally for BMI,
alcohol intake, smoking status, lipid lowering drugs, anti-hypertensive
medication, systolic blood pressure (SBP), TC, HDL-C and TG (models
1–4). The association of GlycA with incident T2DM remained present
after additional adjustment for baseline glucose (model 5). When
hsCRP was added to the model, the relationship of GlycA with T2DM
was still signiﬁcant (model 6). Comparable results were obtained when
GlycA was examined per 1 SD change, although statistical signiﬁcance
was lost after adjustment for hsCRP (data not shown; model 6, HR 1.14
[95% CI: 0.95–1.36, P = 0.16]). hsCRP was also associated with T2DM in
models adjusted for age, sex and additionally for BMI, alcohol intake,
smoking status, lipid lowering drugs, anti-hypertensive medication
and SBP (Table 4, models 1–3), but signiﬁcance was lost after further
Fig. 2. A. Results of linearity testing for the Vantera GlycA assay, solid gray line = linear ﬁt, dotted gray line = polynomial ﬁt; B. Comparison of Vantera and NMR Proﬁler methods
for quantiﬁcation of GlycA, solid gray line = Deming ﬁt, gray line = identity; C. Residual plot for the Deming regression.
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When examined per 1 SD change, hsCRP was also not signiﬁcantly asso-
ciated with incident T2DM in analysis in which we accounted for GlycA
(data not shown; model 6, HR 1.03 [95% CI: 0.87–1.23, P = 0.71]).
Furthermore, in secondary analyses in which the design of the
PREVEND study with preferential inclusion of subjects with elevated
urinary albumin excretion was taken into account, GlycA was still asso-
ciated with incident T2DM after adjustment for hsCRP (Supplementary
Table 1,model 6; HR 1.80 [95% CI: 1.05–3.07, P=0.03]), whereas hsCRP
did not predict T2DM after adjustment for GlycA (Supplementary
Table 1, model 6; HR 1.22 [95% CI: 0.68–2.20, P = 0.86]).
Subsequently, we performed a joint analysis based on dichotomized
subgroups with high and low GlycA or hsCRP (Table 5, Fig. 3). In crude
analysis, the hazard of incident T2DM was highest in the subgroup
with high GlycA and high hsCRP and lowest in the subgroup with lowTable 2
Distribution of GlycA observed in a reference population.
GlycA (μmol/l)
Percentile All
(n = 450)
Men
(n = 158)
Women
(n = 292)
0 245 245 269
2.5 288 273 299
25 346 340 350
50 379 366 388
75 420 394 434
97.5 518 487 522
100 605 605 599GlycA and low hsCRP. After adjustment for age and sex, the hazard for
incident T2DM remained the same in the subgroups with high GlycA
and high hsCRP and high GlycA and low hsCRP, and was only slightly
attenuated in the subgroup with high hsCRP and low GlycA compared
to the subgroup with low GlycA and low hsCRP. Notably, after adjust-
ment for age, sex, BMI, alcohol intake, smoking status, lipid lowering
drugs, antihypertensive medications, SBP, lipids and baseline glucose,
the hazard of incident T2DMwas only signiﬁcantly increased in the sub-
group with high GlycA and low hsCRP.
4. Discussion
Our prospective study is the ﬁrst to show that GlycA, a marker of
systemic inﬂammation, is associated with incident T2DM in a general
population of both men and women. In PREVEND participants GlycA
was an independent predictor of T2DM even after adjusting for tradi-
tional diabetes risk factors and hsCRP. Recently Akinkuolie et al. report-
ed that GlycAwas associatedwith risk of incident T2DM in a population
of initially healthy women enrolled in theWHS [11]. In the WHS study,
the associations of GlycA and hsCRPwith incident T2DMwere attenuat-
ed but remained statistically signiﬁcant after adjusting for diabetes risk
factors. hsCRP remained signiﬁcantly associated with incident T2DM,
while the association with GlycA was no longer signiﬁcant after further
mutual adjustment [11]. In our study, after adjusting for diabetes risk
factors aswell asmutual adjustment, GlycA remained signiﬁcantly asso-
ciated with incident T2DM whereas the association of hsCRP was no
longer signiﬁcant. Moreover, in PREVEND the associations of GlycA
with future T2DM were similar for men and women, while the hsCRP
Table 3
Baseline characteristics according to sex-stratiﬁed quartiles of GlycA in 4524 participants of the PREVEND study.
Quartiles of GlycA, μmol/l
1
Men b 301
Women b 312
2
Men 301–333
Women 312–348
3
Men 334–375
Women 349–390
4
Men ≥ 376
Women ≥ 391
P-value
Participants, n 1134 1117 1146 1127
GlycA, μmol/l 284 [267–296] 324 [315–332] 362 [351–381] 418 [398–448] b0.001
Female, n (%) 599 (52.8) 578 (51.7) 597 (52.1) 588 (52.2) NS
Age, years 48.7 ± 10.5 52.0 ± 11.6 54.2 ± 11.8 55.4 ± 11.7 b0.001
BMI, kg/m2 24.5 ± 3.4 26.0 ± 3.7 27.0 ± 3.9 28.0 ± 4.7 b0.001
Smoking, n (%) b0.001
Never 456 (40.7) 357 (32.4) 281 (24.8) 263 (23.5)
Former 475 (42.4) 500 (45.4) 501 (44.2) 445 (39.8)
Current 189 (16.9) 245 (22.2) 351 (31.0) 409 (36.6)
Alcohol intake, n (%) b0.001
Almost never 202 (18.0) 223 (20.2) 296 (26.0) 323 (28.9)
1–4 drinks per month 192 (17.1) 195 (17.6) 196 (17.2) 188 (16.8)
2–7 drinks per week 425 (37.8) 370 (33.5) 337 (29.6) 318 (28.5)
≥1 drinks per day 305 (27.1) 318 (28.8) 309 (27.2) 287 (25.7)
Lipid lowering drug use, n (%) 44 (3.9) 74 (6.6) 117 (10.2) 154 (13.7) b0.001
SBP, mm Hg 118.6 ± 15.3 123.2 ± 17.2 127.0 ± 19.5 129.7 ± 18.9 b0.001
DBP, mm Hg 70.3 ± 8.7 72.2 ± 8.6 73.8 ± 9.0 74.4 ± 8.8 b0.001
Blood pressure-lowering drug use, n (%) 105 (9.3) 176 (15.8) 260 (22.7) 316 (28.0) b0.001
hsCRP, mg/l 0.50 [0.25–0.93] 0.93 [0.53–1.55] 1.66 [0.93–3.11] 3.43 [1.80–6.85] b0.001
Glucose, mmol/l 4.7 ± 0.6 4.8 ± 0.6 4.9 ± 0.6 5.0 ± 0.7 b0.001
TC, mmol/l 5.2 ± 1.0 5.4 ± 1.0 5.5 ± 1.0 5.7 ± 1.08 b0.001
HDL-C, mmol/l 1.3 ± 0.3 1.3 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 b0.001
TG, mmol/l 0.85 [0.64–1.18] 1.02 [0.77–1.40] 1.20 [0.88–1.64] 1.35 [0.98–1.83] b0.001
Data are expressed asmean± SD, median [IQR] or proportion n (%). P values are calculated by linear regression or χ2 analysis. Diabetes was deﬁned as fasting plasma glucose level N
7.0 mmol/l or non-fasting plasma glucose level N 11.1 mmol/l or use of antidiabetic medication.
Abbreviations: PREVEND, Prevention of REnal and Vascular ENd-stage Disease.
15M.A. Connelly et al. / Clinica Chimica Acta 452 (2016) 10–17associations appeared to be somewhat stronger in women than inmen.
The association of hsCRP with incident T2DM in men was attenuated
after adjustment for medications (model 2; HR 1.13 [95% CI: 0.94–
1.35. P = NS) but remained signiﬁcant in women even after further
adjustment for medications and lipids (model 3; HR 1.28 [95% CI:Table 4
Association of GlycA and hsCRP with incident type 2 diabetes mellitus in the PREVEND study (
Quartile 1 Quartile 2 P value Quartil
GlycA b306 306–340 341–38
Participants (n) 1104 1147 1133
No. of ‘cases’ (%) 26 (2.4) 40 (3.5) 63 (5.6
Person years 7505 7554 7257
Crude 1 1.53 [0.93–2.51] NS 2.52 [1
Model 1 1 1.40 [0.86–2.30] NS 2.24 [1
Model 2 1 1.22 [0.74–2.00] NS 1.75 [1
Model 3 1 1.17 [0.71–1.92] NS 1.52 [0
Model 4 1 1.08 [0.66–1.77] NS 1.33 [0
Model 5 1 1.23 [0.73–2.06] NS 1.64 [1
Model 6 1 1.22 [0.72–2.05] NS 1.61 [0
hsCRP b0.58 0.58–1.25 1.26–2
Participants (n) 1132 1130 1134
No. of ‘cases’ (%) 20 (1.8) 41 (3.6) 74 (6.5
Person years 7703 7485 7148
Crude 1 2.11 [1.24–3.60] 0.006 4.03 [2
Model 1 1 1.85 [1.08–3.16] 0.03 3.27 [1
Model 2 1 1.43 [0.83–2.45] NS 2.12 [1
Model 3 1 1.37 [0.80–2.36] NS 1.94 [1
Model 4 1 1.18 [0.68–2.03] NS 1.64 [0
Model 5 1 1.14 [0.65–1.99] NS 1.58 [0
Model 6 1 1.08 [0.62–1.89] NS 1.45 [0
Hazard ratios were derived from Cox proportional hazards regression models. TG and hsCRP w
Model 1: crude model + age, sex.
Model 2: model 1 + BMI, alcohol intake, smoking status.
Model 3: model 2 + lipid lowering drugs, anti-hypertensive medication and SBP.
Model 4: model 3 + TC, HDL-C, TG.
Model 5: model 4 + baseline glucose.
Model 6: model 5 + hsCRP (for GlycA analysis) and GlycA (for hsCRP analysis).
Abbreviations: PREVEND, Prevention of REnal and Vascular ENd-stage Disease.
⁎ Tests of trend across increasing quartiles were conducted by assigning the median for each1.04–1.59. P = 0.02) and was only attenuated after further adjustment
for baseline glucose (model 4; HR 1.21 [95% CI: 0.97–1.51. P= NS). The
fact that the association of hsCRP, but not GlycA, with incident T2DM is
stronger in women than in menmay explain, at least in part, the differ-
ences in results between these two studies.n= 4524; 220 events).
e 3 P value Quartile 4 P value P for trend⁎
3 ≥384
1140
) 91 (8.0)
6998
.60–3.99] b0.001 3.81 [2.46–5.89] b0.001 b0.001
.41–3.55] 0.001 3.39 [2.18–5.28] b0.001 b0.001
.09–2.79] 0.02 2.14 [1.34–3.41] 0.001 b0.001
.95–2.44] NS 1.82 [1.13–2.91] 0.01 0.004
.82–2.13] NS 1.55 [0.97–2.48] 0.07 0.005
.01–2.66] 0.05 1.77 [1.10–2.86] 0.02 0.01
.98–2.66] NS 1.71 [1.00–2.92] 0.05 0.04
.82 ≥2.83
1128
) 85 (7.5)
6977
.46–6.60] b0.001 4.75 [2.92–7.74] b0.001 b0.001
.98–5.39] b0.001 3.93 [2.40–6.45] b0.001 b0.001
.27–3.53] 0.004 2.10 [1.25–3.54] 0.005 0.02
.16–3.24] 0.01 1.88 [1.11–3.17] 0.02 NS
.98–2.75] NS 1.56 [0.92–2.64] NS NS
.93–2.68] NS 1.47 [0.86–2.51] NS NS
.84–2.48] NS 1.20 [0.67–2.17] NS NS
ere log transformed when used as a continuous variable in the analysis.
quartile as its value and treating this as a continuous variable.
Table 5
Joint analysis of GlycA and hsCRP categories on incident type 2 diabetes mellitus.
Low GlycA
Low hsCRP
Low GlycA
High hsCRP
P value High GlycA
Low hsCRP
P value High GlycA
High hsCRP
P value
Participants (n) 2938 468 458 660
No. of ‘cases’ (%) 101 (3.4) 29 (6.2) 34 (7.4) 56 (8.5)
Crude 1 1.89 [1.25–2.86] 0.002 2.32 [1.57–3.42] b0.001 2.74 [1.98–3.80] b0.001
Model 1 1 1.68 [1.11–2.54] 0.02 2.16 [1.46–3.19] b0.001 2.54 [1.82–3.53] b0.001
Model 2 1 1.19 [0.77–1.83] NS 1.57 [1.04–2.36] 0.03 1.24 [0.86–1.78] NS
Higher levels were deﬁned as greater than the upper quartile for GlycA N384 μmol/l and hsCRP N2.83 mg/l.
Model 1: crude model + age, sex.
Model 2: model 1 + BMI, alcohol intake, smoking status, lipid lowering drugs, anti-hypertensive medication, SBP, baseline glucose and TC, HDL-C, TG.
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tion to hsCRP for the prediction of future T2DM. GlycA is unique in
that it is an NMR signal derived from residues within the carbohydrate
side-chains of multiple acute phase reactants [1]. Not only are the syn-
thesis and secretion of these proteins increased during inﬂammation,
but their glycan structures are dynamically altered [27–30]. For exam-
ple, the carbohydrate side-chains of α1-acid glycoprotein, one of the
acute phase glycoproteins captured in the GlycA signal, become highly
branched and contain additional GlcNAc residues in the context of
chronic inﬂammation and cancer [28,31]. It is plausible that GlycA rep-
resents a composite biomarker with the potential to have disease asso-
ciations that differ, or are even stronger, than individual inﬂammatory
markers [2]. In this regard, it is also relevant that GlycA is less variable
within subjects than hsCRP [1]; in our study, GlycA remained signiﬁ-
cantly associated with incident T2DM even after adjusting for diabetes
risk factors and hsCRP.
Low grade inﬂammation is known to trigger the development of in-
sulin resistance and loss of β-cell function, both of which are proposed
to be implicated in the pathogenesis of T2DM (for review: [32–35]).
Accumulating evidence suggests that carbohydrate metabolism and
the immune system are intricately linked. Nutritional excess leads to
enhanced systemic inﬂammation via multiple mechanisms including
obesity and ensuing adipose tissue inﬂammation and alterations in
the intestinal microbiome [32]. In turn, tissue and circulating inﬂamma-
tory mediators may be causally implicated in the development of
insulin resistance and β-cell dysfunction, factors that are key for the
progression to T2DM [32–35]. Previous studies revealed that there are
increases in individual components of the innate immune system,
including cytokines, complement factors and acute phase proteins,
in subjects with T2DM [36]. In addition, several of these inﬂammatory
markers have been shown to be associated with incident T2DM
[37–41]. Therefore, it makes biological sense that GlycA, a unique
multi-marker of systemic inﬂammation, would be independently relat-
ed to diabetes risk.Fig. 3.Kaplan–Meier curves of diabetes according to joint levels of GlycA and hsCRP.High levels
for hsCRP.It may be possible to combine GlycA with other NMR-measured
metabolic and lipoprotein biomarkers of diabetes risk in order to
increase the speciﬁcity of the prediction for progression to T2DM. For
example, speciﬁc alterations in the lipoprotein particle distribution
occur with insulin resistance and metabolic syndrome [42–44]. In addi-
tion, branched chain amino acids such as valine are associated with
incident T2DM [45–47]. Because GlycA, valine and lipoprotein particle
information can be quantiﬁed simultaneously from the sameNMR spec-
tra of serum or plasma, it would be straightforward to combine these
pieces of information in a single algorithm thatwould predict a patient's
risk of progressing to T2DM. Studies investigating the utility of GlycA in
this regard are ongoing.
The successful development of a high-throughput method to
measure GlycA on a fully automated platform allows NMR technology
dissemination into the routine clinical laboratory setting and creates
the opportunity for NMR-based testing across a broader range of clinical
applications [14,15]. The performance characteristics of the GlycA test
on the presently used device underscores that it is suitable for clinical
applications. Furthermore, high-throughput measurements of GlycA
allow both physician use as well as efﬁcient exploration of additional
disease associations in large clinical studies like PREVEND.
We acknowledge several strengths and weaknesses in our study.
Our study included a large number of participants. Notably, the
PREVEND study was designed to study the impact albuminuria on
renal and cardiovascular outcome. Thus, subjectswere preferentially re-
cruited on the basis of their urinary albumin concentrations; approxi-
mately two thirds having urinary albumin concentrations ≥10 mg/l
and one third having b10 mg/l at the start of this cohort study. For
this reason we performed a secondary analysis taking account of the
design of the PREVEND study. This analysis revealed no differences in
the results or conclusions that were drawn for the entire population.
This ﬁnding is also relevant because albuminuria itself may confer in-
creased risk of diabetes development [48]. In addition, it should be ap-
preciated that most PREVEND participants were of Caucasian descent,of GlycAwere deﬁned as higher than top quartile, i.e. N384 μmol/l for GlycA and N2.84mg/l
17M.A. Connelly et al. / Clinica Chimica Acta 452 (2016) 10–17possibly limiting extrapolation of our ﬁndings to other populations.
Nonetheless, we were able to extend the results obtained in an initially
healthy large population of US women [11].
In conclusion, GlycA, an assay that is available for testing on the
Vantera® Clinical Analyzer, may be useful as a diagnostic indicator for
risk of T2DM, alone or in combination with other NMR-measured
analytes, particularly in a population with abnormal urinary albumin.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cca.2015.11.001.
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